 |
|  |
Jan-03-19 | Upgrade |
UBS |
Neutral → Buy |
|
|
Oct-09-18 | Initiated |
UBS |
Neutral |
|
|
Aug-07-18 | Upgrade |
Morgan Stanley |
Underweight → Equal-Weight |
|
|
Jul-31-18 | Reiterated |
Canaccord Genuity |
Buy |
$330 → $340 |
|
Feb-05-18 | Upgrade |
Citigroup |
Neutral → Buy |
|
|
Jan-31-18 | Upgrade |
First Analysis Sec |
Equal-Weight → Overweight |
$277 |
|
Jan-05-18 | Initiated |
BTIG Research |
Neutral |
|
|
Jan-05-18 | Downgrade |
William Blair |
Outperform → Mkt Perform |
|
|
Jan-02-18 | Upgrade |
Wells Fargo |
Market Perform → Outperform |
|
|
Oct-25-17 | Upgrade |
Robert W. Baird |
Neutral → Outperform |
$184 → $228 |
|
Oct-23-17 | Upgrade |
Janney |
Sell → Neutral |
|
|
Oct-23-17 | Upgrade |
Deutsche Bank |
Hold → Buy |
$195 → $250 |
|
Sep-26-17 | Resumed |
Goldman |
Neutral |
$200 |
|
Aug-07-17 | Upgrade |
Canaccord Genuity |
Hold → Buy |
$170 → $215 |
|
Aug-02-17 | Upgrade |
First Analysis Sec |
Underweight → Equal-Weight |
|
|
Apr-26-17 | Reiterated |
Cantor Fitzgerald |
Neutral |
$155 → $170 |
|
Mar-20-17 | Upgrade |
Leerink Partners |
Mkt Perform → Outperform |
|
|
Feb-01-17 | Reiterated |
UBS |
Buy |
$180 → $185 |
|
Jan-18-17 | Initiated |
Deutsche Bank |
Hold |
$160 |
|
Jan-10-17 | Upgrade |
BofA/Merrill |
Neutral → Buy |
|
|
|
 |
Feb-15-19 01:50PM | Final trades: GE, Royal Caribbean, Illumina, Cisco & Invitation Homes CNBC Videos |
Feb-14-19 06:01PM | Stanley Druckenmiller's Top 6 Buys for the 4th Quarter GuruFocus.com |
Feb-12-19 03:27PM | Illumina Could Rally to Break Its Downtrend TheStreet.com |
11:40AM | The Best S&P 500 Stocks of 2018 Investopedia |
10:48AM | Illumina Inc (ILMN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com |
10:01AM | Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y Zacks |
Feb-11-19 05:03PM | The 1 Stock I'd Buy Right Now Motley Fool |
Feb-10-19 09:00AM | The $100 Billion Investing Opportunity That Could Revolutionize Cancer Treatment Motley Fool |
09:00AM | Health Care Is About to Improve Dramatically; Here's How to Play it TheStreet.com |
Feb-08-19 08:00AM | Factors of Influence in 2019, Key Indicators and Opportunity within The Estee Lauder Companies, The New York Times, Twenty-First Century Fox, Kemet, Illumina, and Computer Programs and New Research Emphasizes Economic Growth GlobeNewswire |
Feb-06-19 08:55AM | Illumina Names Susan E. Siegel to Its Board of Directors Business Wire |
Feb-04-19 01:36PM | Final trades ahead of a big batch of earnings CNBC Videos |
Feb-03-19 10:09AM | The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs Benzinga |
09:00AM | 5 Things to Expect From Illumina in 2019 Motley Fool |
Feb-01-19 01:42PM | Final trades: Chevron, Illumina, Nvidia & KKR CNBC Videos |
07:10AM | Illumina, Inc. (NASDAQ:ILMN): Will The Growth Last? Simply Wall St. |
Jan-31-19 09:30AM | CBM or ILMN: Which Is the Better Value Stock Right Now? Zacks |
07:13AM | Edited Transcript of ILMN earnings conference call or presentation 29-Jan-19 10:00pm GMT Thomson Reuters StreetEvents |
Jan-30-19 05:01PM | What Happened in the Stock Market Today Motley Fool |
01:45PM | Illumina Sinks on Fourth-Quarter Earnings Miss TheStreet.com |
10:58AM | Morgan Stanley: Illumina's Q1 Guidance Puts 2019 Targets In Question Benzinga |
09:58AM | Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark Zacks |
09:07AM | Illumina Stock Drops, Pandora Rises and Three More Wednesday Morning Movers Barrons.com |
08:16AM | Why Illumina's Growth Rate Slowed in the Fourth Quarter -- Temporarily Motley Fool |
08:12AM | The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance Benzinga |
07:23AM | Dow Jones Futures: Apple, AMD Drive Premarket Rally Investor's Business Daily |
04:14AM | Illumina (ILMN) Q4 2018 Earnings Conference Call Transcript Motley Fool |
Jan-29-19 05:34PM | Illumina: 4Q Earnings Snapshot Associated Press |
05:25PM | Illumina Earnings Mixed, But Stryker Stock Pops On Quarterly Beat Investor's Business Daily |
04:05PM | Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2018 Business Wire |
11:07AM | Illumina Earnings miss, Revenue beats In Q4 Investing.com |
09:54AM | Thermo Fisher (TMO) Down on Business Divestment Declaration Zacks |
09:54AM | Here's Why You Should Snap Up Abbott (ABT) Stock Right Now Zacks |
07:24AM | Illumina's Q4 Earnings Outlook Benzinga |
Jan-28-19 10:12AM | Cerner (CERN) to Report Q4 Earnings: What's in the Cards? Zacks |
07:29AM | Will Core Business Units Boost McKesson's (MCK) Q3 Earnings? Zacks |
Jan-27-19 06:05PM | 3 Top Healthcare Growth Stocks to Buy in 2019 Motley Fool |
05:15PM | 3 Things You Can Expect From Illumina's Q4 Earnings Update Motley Fool |
Jan-25-19 02:41PM | 5 Innovation-Led Stocks For The Health Care Boom Investopedia |
09:49AM | Will Lower Revenues Dampen Juniper's (JNPR) Q4 Earnings? Zacks |
08:53AM | AmerisourceBergen (ABC) Q1 Earnings: What's in the Cards? Zacks |
08:24AM | Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now Zacks |
08:12AM | What's in Store for Edwards Lifesciences' (EW) Q4 Earnings? Zacks |
Jan-24-19 01:49PM | Will Top-Line Growth Support Corning's (GLW) Q4 Earnings? Zacks |
11:41AM | Will GPU Product Introduction Benefit AMD's Q4 Earnings? Zacks |
11:15AM | Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings? Zacks |
10:19AM | What's Setting the Tone for Hologic's (HOLX) Q1 Earnings? Zacks |
10:03AM | Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings? Zacks |
06:12AM | Factors Expected to Influence Microsoft's (MSFT) Q2 Earnings Zacks |
Jan-23-19 05:05PM | 3 Top Healthcare Stocks to Buy in January Motley Fool |
03:13PM | Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised) Zacks |
01:19PM | Final Trades: T-Mobile, Illumina, Bristol-Myers. Plus, Ma... CNBC Videos |
09:16AM | Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings? Zacks |
09:13AM | Can Overall Growth Fuel Align Technology's (ALGN) Q4 Earnings? Zacks |
Jan-22-19 08:13AM | ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio Zacks |
Jan-21-19 10:02AM | Quest Diagnostics' Core Diagnostics Strong Amid Several Woes Zacks |
07:58AM | Neogen Gains on Strong Genomic Arm Amid Stiff Competition Zacks |
Jan-18-19 08:00PM | Five Ways to Profit from the Boom in Life Science Barrons.com |
10:00AM | Illumina (ILMN) Is Up 1.45% in One Week: What You Should Know Zacks |
08:59AM | Here is Why Growth Investors Should Buy Illumina (ILMN) Now Zacks |
08:44AM | Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings? Zacks |
08:06AM | Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now Zacks |
Jan-17-19 08:58AM | Henry Schein Animal Health Spin-Off Approaches, Cost Mounts Zacks |
Jan-16-19 05:50PM | Illumina (ILMN) Gains But Lags Market: What You Should Know Zacks |
12:08PM | REIT Stocks, Medical Stocks Lead New Buys By The Best Mutual Funds Investor's Business Daily |
09:58AM | The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana Zacks |
09:32AM | Why You Should Consider Buying Omnicell (OMCL) Stock Now Zacks |
Jan-15-19 04:05PM | Illumina to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Tuesday, January 29, 2019 Business Wire |
07:26AM | 5 Great Medical Stocks to Buy Ahead of Q4 Earnings Zacks |
06:19AM | QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands Zacks |
Jan-14-19 07:07AM | Here's Why You Should Invest in Illumina (ILMN) Stock Now Zacks |
Jan-13-19 07:00AM | Here's Why Illumina Gained 37.3% in 2018 Motley Fool |
Jan-11-19 09:30AM | Has Illumina (ILMN) Outpaced Other Medical Stocks This Year? Zacks |
Jan-10-19 09:15AM | Stocks Stay Positive on Trade Hopes, Still Patient Fed Zacks |
Jan-09-19 07:01AM | Illumina sees Q4 revenue above expectations, provides a mixed outlook MarketWatch |
Jan-08-19 09:30PM | Why Investors Didn't Like Illumina's J.P. Morgan Presentation -- but Should Have Motley Fool |
05:04PM | What Happened in the Stock Market Today Motley Fool |
04:28PM | This IBD 50 Medical Giant Is Diving On Its Outlook But 'Don't Panic' Investor's Business Daily |
10:10AM | Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again Zacks |
08:15AM | The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase Benzinga |
Jan-07-19 05:50PM | Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know Zacks |
03:53PM | Top 5 Health Care Stocks of 2018 by Performance Investopedia |
12:27PM | Heres What Illumina, Inc.s (NASDAQ:ILMN) P/E Is Telling Us Simply Wall St. |
06:50AM | Today's Research Reports on Trending Tickers: Exact Sciences and Illumina ACCESSWIRE |
Dec-27-18 04:10PM | Why This IBD Stock Of The Day 'Continues To Push For New Highs' Investor's Business Daily |
02:45PM | Robots, DNA And Implantable Devices Why 2019 Isn't Your Dad's Medtech Investor's Business Daily |
09:15AM | Christmas Comes a Day Late Zacks |
Dec-26-18 08:17AM | 3 Medical Stocks Likely to Emulate Illumina's Success in 2019 Zacks +7.67% |
Dec-24-18 09:28AM | These Growth Stocks Drive This Mutual Fund's Special Outperformance Investor's Business Daily |
Dec-21-18 01:36PM | 6 Genome Sequencing Stocks to Buy for Big Health-Care Profits Kiplinger |
09:15AM | Stocks Still Angry at the Fed; Drop Another 1.5%+ Zacks |
Dec-20-18 04:05PM | Illumina to Webcast Upcoming Investor Conference Presentations Business Wire |
08:48AM | 5 Blue Chip Stocks to Lead Despite Rising Global Shocks Investopedia |
Dec-17-18 09:05AM | Here's Why You Should Buy Express Scripts (ESRX) Stock Now Zacks |
Dec-14-18 10:25AM | AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals Zacks |
06:43AM | Here's Why You Should Hold Allscripts Stock in Your Portfolio Zacks |
Dec-13-18 07:32AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
Dec-12-18 01:51PM | 10 Stocks That Can Move Higher Whatever Happens InvestorPlace |
09:30AM | Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks |
08:16AM | BD Gets Enterprise Level Cybersecurity Assessment From UL Zacks |
|
|
|
 |
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
FLATLEY JAY T | Director | Feb 13 | Sale | 293.66 | 3,300 | 969,078 | 344,868 | Feb 14 04:21 PM | RAGUSA ROBERT P | SVP, Global Quality & Ops | Feb 12 | Option Exercise | 0.00 | 4,540 | 0 | 15,316 | Feb 14 04:32 PM | Van Oene Mark | SVP Chief Commercial Officer | Feb 12 | Option Exercise | 0.00 | 5,639 | 0 | 15,419 | Feb 14 04:36 PM | FLATLEY JAY T | Director | Feb 12 | Option Exercise | 0.00 | 28,888 | 0 | 358,929 | Feb 14 04:21 PM | Ronaghi Mostafa | SVP & CTO | Feb 12 | Option Exercise | 0.00 | 9,782 | 0 | 79,217 | Feb 14 04:34 PM | deSouza Francis A | President and CEO | Feb 12 | Option Exercise | 0.00 | 24,621 | 0 | 82,910 | Feb 14 04:17 PM | Dadswell Charles | SVP & General Counsel | Feb 12 | Option Exercise | 0.00 | 4,127 | 0 | 11,064 | Feb 14 04:15 PM | OSTADAN OMEAD | SVP Mktg, Prod & Strat Plan | Feb 12 | Option Exercise | 0.00 | 9,492 | 0 | 33,875 | Feb 14 04:23 PM | EPSTEIN ROBERT S | Director | Feb 01 | Option Exercise | 51.17 | 1,000 | 51,170 | 4,256 | Feb 05 04:45 PM | Dadswell Charles | SVP & General Counsel | Feb 01 | Sale | 280.11 | 124 | 34,734 | 6,879 | Feb 05 04:44 PM | deSouza Francis A | President and CEO | Feb 01 | Sale | 282.95 | 3,000 | 848,854 | 64,104 | Feb 05 04:46 PM | EPSTEIN ROBERT S | Director | Feb 01 | Sale | 280.11 | 1,000 | 280,110 | 3,256 | Feb 05 04:45 PM | FLATLEY JAY T | Director | Jan 23 | Sale | 303.53 | 3,300 | 1,001,649 | 329,979 | Jan 25 04:27 PM | FLATLEY JAY T | Director | Jan 09 | Sale | 296.20 | 3,300 | 977,460 | 333,279 | Jan 11 04:35 PM | EPSTEIN ROBERT S | Director | Jan 02 | Option Exercise | 51.17 | 1,000 | 51,170 | 4,256 | Jan 04 05:05 PM | EASTHAM KARIN | Director | Jan 02 | Option Exercise | 71.09 | 4,000 | 284,360 | 15,838 | Jan 04 05:03 PM | EPSTEIN ROBERT S | Director | Jan 02 | Sale | 294.71 | 1,000 | 294,710 | 3,256 | Jan 04 05:05 PM | EASTHAM KARIN | Director | Jan 02 | Sale | 294.08 | 5,000 | 1,470,381 | 10,838 | Jan 04 05:03 PM | deSouza Francis A | President and CEO | Jan 02 | Sale | 293.33 | 3,000 | 879,994 | 67,104 | Jan 04 05:04 PM | Dadswell Charles | Sr VP & General Counsel | Jan 02 | Sale | 294.71 | 124 | 36,544 | 7,003 | Jan 04 05:01 PM | FLATLEY JAY T | Director | Dec 26 | Sale | 273.87 | 3,300 | 903,771 | 336,579 | Dec 28 05:36 PM | FLATLEY JAY T | Director | Dec 12 | Sale | 334.13 | 3,300 | 1,102,629 | 371,559 | Dec 13 07:26 PM | OSTADAN OMEAD | EVP Ops, Products, Strategy | Dec 10 | Sale | 321.50 | 644 | 207,046 | 21,613 | Dec 12 01:59 PM | Stapley Marc | EVP Strategy & Corp Developmt | Dec 06 | Sale | 329.69 | 1,000 | 329,695 | 6,957 | Dec 07 05:17 PM | EPSTEIN ROBERT S | Director | Dec 03 | Option Exercise | 51.17 | 1,000 | 51,170 | 6,101 | Dec 04 09:03 PM | Dadswell Charles | Sr VP & General Counsel | Dec 03 | Sale | 343.57 | 566 | 194,461 | 5,606 | Dec 04 09:01 PM | EPSTEIN ROBERT S | Director | Dec 03 | Sale | 343.57 | 1,345 | 462,102 | 4,756 | Dec 04 09:03 PM | deSouza Francis A | President and CEO | Dec 03 | Sale | 345.90 | 3,000 | 1,037,688 | 63,643 | Dec 04 09:02 PM | FLATLEY JAY T | Director | Nov 28 | Sale | 321.80 | 3,300 | 1,061,940 | 373,410 | Nov 30 04:24 PM | OSTADAN OMEAD | EVP Ops, Products, Strategy | Nov 23 | Sale | 306.74 | 644 | 197,541 | 22,257 | Nov 27 04:39 PM | FLATLEY JAY T | Director | Nov 14 | Sale | 312.50 | 3,300 | 1,031,250 | 376,710 | Nov 16 04:09 PM | Ronaghi Mostafa | Sr VP & CTO | Nov 12 | Option Exercise | 37.04 | 10,000 | 370,400 | 79,612 | Nov 14 05:44 PM | Ronaghi Mostafa | Sr VP & CTO | Nov 12 | Sale | 314.63 | 10,000 | 3,146,337 | 69,612 | Nov 14 05:44 PM | Stapley Marc | EVP Strategy & Corp Developmt | Nov 07 | Sale | 336.68 | 1,000 | 336,680 | 6,957 | Nov 09 04:23 PM | Van Oene Mark | SVP Chief Commercial Officer | Nov 05 | Option Exercise | 29.44 | 6,000 | 176,640 | 17,126 | Nov 07 05:05 PM | Van Oene Mark | SVP Chief Commercial Officer | Nov 05 | Sale | 326.11 | 6,835 | 2,228,950 | 10,291 | Nov 07 05:05 PM | EPSTEIN ROBERT S | Director | Nov 01 | Option Exercise | 51.17 | 1,000 | 51,170 | 6,447 | Nov 02 05:01 PM | deSouza Francis A | President and CEO | Nov 01 | Sale | 310.85 | 2,100 | 652,788 | 70,235 | Nov 02 05:03 PM | EPSTEIN ROBERT S | Director | Nov 01 | Sale | 311.86 | 1,346 | 419,764 | 5,101 | Nov 02 05:01 PM | FLATLEY JAY T | Director | Oct 24 | Sale | 310.58 | 3,300 | 1,024,914 | 382,304 | Oct 26 04:35 PM | Ronaghi Mostafa | Sr VP & CTO | Oct 10 | Option Exercise | 37.04 | 10,000 | 370,400 | 80,805 | Oct 12 04:37 PM | Ronaghi Mostafa | Sr VP & CTO | Oct 10 | Sale | 311.84 | 10,000 | 3,118,424 | 70,805 | Oct 12 04:37 PM | FLATLEY JAY T | Director | Oct 10 | Sale | 321.58 | 3,300 | 1,061,214 | 385,604 | Oct 12 04:35 PM | EPSTEIN ROBERT S | Director | Oct 01 | Option Exercise | 51.17 | 1,000 | 51,170 | 6,793 | Oct 03 04:17 PM | deSouza Francis A | President and CEO | Oct 01 | Sale | 369.61 | 2,100 | 776,183 | 72,335 | Oct 03 04:20 PM | EPSTEIN ROBERT S | Director | Oct 01 | Sale | 369.15 | 1,346 | 496,876 | 5,447 | Oct 03 04:17 PM | FLATLEY JAY T | Director | Sep 26 | Sale | 360.81 | 3,300 | 1,190,673 | 388,904 | Sep 28 05:29 PM | FLATLEY JAY T | Director | Sep 12 | Sale | 351.66 | 3,300 | 1,160,478 | 392,204 | Sep 14 09:25 PM | Ronaghi Mostafa | Sr VP & CTO | Sep 10 | Option Exercise | 37.04 | 10,000 | 370,400 | 80,805 | Sep 11 05:49 PM | Ronaghi Mostafa | Sr VP & CTO | Sep 10 | Sale | 347.07 | 10,000 | 3,470,709 | 70,805 | Sep 11 05:49 PM | EPSTEIN ROBERT S | Director | Sep 07 | Option Exercise | 51.17 | 1,000 | 51,170 | 7,139 | Sep 11 05:45 PM | EPSTEIN ROBERT S | Director | Sep 07 | Sale | 345.14 | 1,346 | 464,558 | 5,793 | Sep 11 05:45 PM | Van Oene Mark | SVP Chief Commercial Officer | Sep 04 | Sale | 354.18 | 1,091 | 386,410 | 11,126 | Sep 06 06:09 PM | deSouza Francis A | President and CEO | Sep 04 | Sale | 353.66 | 2,100 | 742,686 | 74,435 | Sep 06 06:26 PM | Stapley Marc | EVP Strategy & Corp Developmt | Sep 04 | Sale | 352.05 | 1,000 | 352,054 | 8,516 | Sep 06 08:22 PM | Ronaghi Mostafa | Sr VP & CTO | Aug 10 | Option Exercise | 37.04 | 10,000 | 370,400 | 80,805 | Aug 14 04:07 PM | Ronaghi Mostafa | Sr VP & CTO | Aug 10 | Sale | 331.39 | 10,000 | 3,313,861 | 70,805 | Aug 14 04:07 PM | Stapley Marc | EVP Strategy & Corp Developmt | Aug 02 | Sale | 324.80 | 1,000 | 324,798 | 7,516 | Aug 06 08:10 PM | OSTADAN OMEAD | EVP Ops, Products, Strategy | Aug 02 | Sale | 320.70 | 1,334 | 427,814 | 24,484 | Aug 06 08:11 PM | deSouza Francis A | President and CEO | Aug 01 | Sale | 327.41 | 2,100 | 687,555 | 76,535 | Aug 03 03:03 PM | EPSTEIN ROBERT S | Director | Jul 23 | Sale | 311.15 | 500 | 155,575 | 6,139 | Jul 24 07:21 PM | deSouza Francis A | President and CEO | Jul 12 | Sale | 300.00 | 3,300 | 990,000 | 78,635 | Jul 13 02:39 PM | Ronaghi Mostafa | Sr VP & CTO | Jul 10 | Option Exercise | 37.04 | 7,500 | 277,800 | 78,496 | Jul 12 07:39 PM | Ronaghi Mostafa | Sr VP & CTO | Jul 10 | Sale | 288.89 | 7,500 | 2,166,701 | 70,996 | Jul 12 07:39 PM | deSouza Francis A | President and CEO | Jul 02 | Sale | 276.14 | 2,100 | 579,887 | 82,271 | Jul 03 06:20 PM | EPSTEIN ROBERT S | Director | Jun 21 | Sale | 288.45 | 500 | 144,225 | 6,639 | Jun 22 07:12 PM | Ronaghi Mostafa | Sr VP & CTO | Jun 11 | Option Exercise | 28.45 | 10,500 | 298,725 | 81,496 | Jun 13 06:21 PM | Stapley Marc | EVP Strategy & Corp Developmt | Jun 11 | Sale | 285.18 | 1,446 | 412,364 | 8,516 | Jun 13 06:24 PM | Ronaghi Mostafa | Sr VP & CTO | Jun 11 | Sale | 284.83 | 10,500 | 2,990,759 | 70,996 | Jun 13 06:21 PM | deSouza Francis A | President and CEO | Jun 01 | Sale | 272.91 | 2,100 | 573,107 | 84,371 | Jun 04 08:54 PM | OSTADAN OMEAD | EVP Ops, Products, Strategy | Jun 01 | Sale | 274.61 | 1,335 | 366,604 | 25,818 | Jun 04 08:57 PM | EPSTEIN ROBERT S | Director | May 21 | Sale | 271.00 | 500 | 135,500 | 6,588 | May 22 05:25 PM | EASTHAM KARIN | Director | May 21 | Sale | 269.80 | 1,000 | 269,802 | 12,288 | May 22 05:23 PM | Ronaghi Mostafa | Sr VP & CTO | May 16 | Option Exercise | 28.45 | 10,000 | 284,500 | 80,996 | May 18 07:39 PM | Ronaghi Mostafa | Sr VP & CTO | May 16 | Sale | 267.71 | 10,000 | 2,677,135 | 70,996 | May 18 07:39 PM | FLATLEY JAY T | Director | May 14 | Sale | 268.00 | 1,460 | 391,280 | 4,000 | May 16 09:40 PM | deSouza Francis A | President and CEO | May 14 | Sale | 268.63 | 2,100 | 564,124 | 86,471 | May 16 09:37 PM | OSTADAN OMEAD | EVP Ops, Products, Strategy | May 02 | Sale | 242.60 | 1,314 | 318,776 | 27,153 | May 04 06:53 PM | BOWMAN A BLAINE | Director | May 01 | Option Exercise | 55.14 | 3,000 | 165,426 | 19,868 | May 03 06:23 PM | BOWMAN A BLAINE | Director | May 01 | Sale | 241.45 | 3,000 | 724,336 | 16,868 | May 03 06:23 PM | Van Oene Mark | SVP Chief Commercial Officer | Apr 12 | Sale | 238.48 | 1,400 | 333,872 | 12,217 | Apr 13 07:30 PM | Dadswell Charles | Sr VP & General Counsel | Apr 03 | Sale | 230.91 | 116 | 26,786 | 7,875 | Apr 04 07:32 PM | BOWMAN A BLAINE | Director | Apr 02 | Option Exercise | 44.51 | 3,000 | 133,530 | 19,868 | Apr 04 07:29 PM | BOWMAN A BLAINE | Director | Apr 02 | Sale | 230.13 | 3,000 | 690,383 | 16,868 | Apr 04 07:29 PM | ARNOLD FRANCES | Director | Mar 15 | Sale | 252.26 | 250 | 63,065 | 10,189 | Mar 15 07:56 PM | ARNOLD FRANCES | Director | Mar 08 | Sale | 241.50 | 250 | 60,375 | 10,439 | Mar 08 07:50 PM | Stapley Marc | EVP Strategy & Corp Developmt | Mar 06 | Sale | 233.64 | 2,000 | 467,288 | 13,787 | Mar 08 07:45 PM | EASTHAM KARIN | Director | Mar 05 | Option Exercise | 71.09 | 2,000 | 142,180 | 15,288 | Mar 06 07:17 PM | EASTHAM KARIN | Director | Mar 05 | Sale | 229.37 | 2,000 | 458,735 | 13,288 | Mar 06 07:17 PM | Dadswell Charles | Sr VP & General Counsel | Mar 05 | Sale | 227.17 | 145 | 32,940 | 7,991 | Mar 06 07:13 PM | OSTADAN OMEAD | EVP Ops, Products, Strategy | Mar 02 | Sale | 222.66 | 1,329 | 295,916 | 28,467 | Mar 05 09:03 PM | BOWMAN A BLAINE | Director | Mar 01 | Option Exercise | 44.51 | 3,000 | 133,530 | 19,868 | Mar 05 08:12 PM | BOWMAN A BLAINE | Director | Mar 01 | Sale | 227.01 | 3,000 | 681,028 | 16,868 | Mar 05 08:12 PM | EPSTEIN ROBERT S | Director | Feb 28 | Sale | 231.25 | 250 | 57,813 | 7,088 | Mar 02 07:06 PM |
|
 |
|
 |
|